Top ▲
Gene and Protein Information | ||||||
Species | TM | AA | Chromosomal Location | Gene Symbol | Gene Name | Reference |
Human | - | 837 | 1q23.3 | ADAMTS4 | ADAM metallopeptidase with thrombospondin type 1 motif 4 | |
Mouse | - | 833 | 1 79.28 cM | Adamts4 | ADAM metallopeptidase with thrombospondin type 1 motif 4 | |
Rat | - | 630 | 13q24 | Adamts4 | ADAM metallopeptidase with thrombospondin type 1 motif, 4 |
Database Links | |
Specialist databases | |
MEROPS | M12.221 (Hs) |
Other databases | |
Alphafold | O75173 (Hs), Q8BNJ2 (Mm), Q9ESP7 (Rn) |
BRENDA | 3.4.24.82 |
CATH/Gene3D | 2.20.100.10, 3.40.390.10 |
ChEMBL Target | CHEMBL2318 (Hs), CHEMBL4523453 (Rn) |
Ensembl Gene | ENSG00000158859 (Hs), ENSMUSG00000006403 (Mm), ENSRNOG00000003538 (Rn) |
Entrez Gene | 9507 (Hs), 240913 (Mm), 66015 (Rn) |
Human Protein Atlas | ENSG00000158859 (Hs) |
KEGG Enzyme | 3.4.24.82 |
KEGG Gene | hsa:9507 (Hs), mmu:240913 (Mm), rno:66015 (Rn) |
OMIM | 603876 (Hs) |
Pharos | O75173 (Hs) |
RefSeq Nucleotide | NM_005099 (Hs), NM_172845 (Mm), NM_023959 (Rn) |
RefSeq Protein | NP_005090 (Hs), NP_766433 (Mm), NP_076449 (Rn) |
UniProtKB | O75173 (Hs), Q8BNJ2 (Mm), Q9ESP7 (Rn) |
Wikipedia | ADAMTS4 (Hs) |
Enzyme Reaction | ||||
|
Download all structure-activity data for this target as a CSV file
Inhibitors | |||||||||||||||||||||||||||||||||||||||||||||||||||
Key to terms and symbols | View all chemical structures | Click column headers to sort | |||||||||||||||||||||||||||||||||||||||||||||||||
|
Immunopharmacology Comments |
ADAMTS4 and -5 diminish cartilage integrity in rheumatoid arthritis (RA) by catalysing degradation of aggrecan [3-4]. The activity of ADAMTS4 has been implicated in inducing excessive fibroblast activity and lower respiratory tract tissue damage in viral infection-related acute respiratory distress syndrome (ARDS) [1]. This suggests that inhibition of ADAMTS4 protease activity might be applicable to limit lung damage and improve clinical outcomes following severe respiratory infections. |
Immuno Disease Associations | ||||||||||
|
||||||||||
|
1. Boyd DF, Allen EK, Randolph AG, Guo X-ZJ, Weng Y, Sanders CJ, Bajracharya R, Lee NK, Guy CS, Vogel P et al.. (2020) Exuberant fibroblast activity compromises lung function via ADAMTS. Nature, [Online ahead of print]. DOI: 10.1038/s41586-020-2877-5 [PMID:33116313]
2. De Savi C, Pape A, Sawyer Y, Milne D, Davies C, Cumming JG, Ting A, Lamont S, Smith PD, Tart J et al.. (2011) Orally active achiral N-hydroxyformamide inhibitors of ADAM-TS4 (aggrecanase-1) and ADAM-TS5 (aggrecanase-2) for the treatment of osteoarthritis. Bioorg Med Chem Lett, 21 (11): 3301-6. [PMID:21536437]
3. McInnes IB, Schett G. (2011) The pathogenesis of rheumatoid arthritis. N Engl J Med, 365 (23): 2205-19. [PMID:22150039]
4. Porter S, Clark IM, Kevorkian L, Edwards DR. (2005) The ADAMTS metalloproteinases. Biochem J, 386 (Pt 1): 15-27. [PMID:15554875]
5. Song RH, Tortorella MD, Malfait AM, Alston JT, Yang Z, Arner EC, Griggs DW. (2007) Aggrecan degradation in human articular cartilage explants is mediated by both ADAMTS-4 and ADAMTS-5. Arthritis Rheum, 56 (2): 575-85. [PMID:17265492]
6. Yamanishi Y, Boyle DL, Clark M, Maki RA, Tortorella MD, Arner EC, Firestein GS. (2002) Expression and regulation of aggrecanase in arthritis: the role of TGF-beta. J Immunol, 168 (3): 1405-12. [PMID:11801682]
M12: Astacin/Adamalysin: ADAMTS4. Last modified on 29/10/2020. Accessed on 04/12/2024. IUPHAR/BPS Guide to PHARMACOLOGY, https://www.guidetomalariapharmacology.org/GRAC/ObjectDisplayForward?objectId=1677.